药物涂层球囊治疗冠状动脉药物洗脱支架内再狭窄临床分析.doc

药物涂层球囊治疗冠状动脉药物洗脱支架内再狭窄临床分析 目录 TOC \o 1-9 \h \z \u 目录 1 正文 1 文1：药物涂层球囊治疗冠状动脉药物洗脱支架内再狭窄临床分析 1 1 资料与方法 3 2 结果 3 3 讨论 4 文2：关于切割球囊成形术治疗冠状动脉支架内再狭窄19例疗效观察 6 1 临床资料 6 2 结果 7 参考文摘引言： 8 原创性声明（模板） 10 文章致谢（模板） 10 正文 药物涂层球囊治疗冠状动脉药物洗脱支架内再狭窄临床分析 文1：药物涂层球囊治疗冠状动脉药物洗脱支架内再狭窄临床分析 [Abstract] Objective To analyze the efficacy of the drug coated balloon （DCB） for treating in-stent restenosis of drug eluting stent （DES） in coronary artery. Methods The clinical data and follow-up results of 20 patients with in-stent restenosis after percutaneous coronary DES implantation were retrospectively analyzed. Results A total of 20 patients with 21 in-stent restenosis lesio underwent DCB treatment， with % immediate success rate. After application of DCB treatment， 1 lesion complicated with dissection and TIMI grade 2 flow. Afterwards， the implantation of DES was involved. During the follow-up， no angina and major advee cardiovascular events had occurred in all cases after the operation so far， among which 12 patients received coronary angiography in post-operative 6-9 months. Compared target lesion minimal lumen diameter with post-operative immediate target lesion minimal lumen diameter， the difference was not statistically significant （P） by the lesion vessels； but the difference had statistical significance （P） by all vessels. Conclusio The immediate and short-term efficacy of DCB for treating in-stent restenosis of DES is positive and reliable. Therefore， it could be a new therapy for the in-stent restenosis。 [Key words] Drug coated balloon； Drug eluting stent； In-stent restenosis； Percutaneous coronary intervention 药物洗脱支架（drug-eluting stent，DES）较裸金属支架大大降低了支架内再狭窄的发生率，但DES亦存在5%～20%的再狭窄率，同时存在晚期支架内血栓等问题[1，2]。近年来我国接受冠状动脉介入治疗的病例数呈井喷性增长，因此支架内再狭窄（in-stent restenosis，ISR）问题日益突出，目前仍是悬而未决的难题。2004年德国学者首次证明了药物涂层球囊（drug coated balloon，DCB）在预防ISR方面的安全性和有效性[3]。随着临床研究的广泛开展，DCB在治疗DES再狭窄方面的安全性和有效性得到了进一步的证实。目前，临床研究最多的DCB为SeQuent Please球囊（贝朗医疗，德国）。国内在应用DCB治疗药物洗脱支架内再狭窄方面尚缺乏大样本的临床经